Loading...
Development of a novel humanized anti-TSLP monoclonal antibody HZ-1127 with anti-allergic diseases and cancer potential
Liu, Xiaolei Han, Jianzhong Wang, Qian Wang, Peng Li, Li Du, Kehe Jiang, Fengchao Zhang, Pei Liu, Hongjun Huang, Jian
Liu, Xiaolei
Han, Jianzhong
Wang, Qian
Wang, Peng
Li, Li
Du, Kehe
Jiang, Fengchao
Zhang, Pei
Liu, Hongjun
Huang, Jian
Citations
Altmetric:
Genre
Journal article
Date
2024-02-27
Advisor
Committee member
Department
Pathology and Laboratory Medicine
Permanent link to this record
Collections
Files
Research Projects
Organizational Units
Journal Issue
DOI
https://doi.org/10.1093/abt/tbae006
Abstract
Thymic stromal lymphopoietin (TSLP) is a member of the IL-2 cytokine family and has been widely recognized as a master regulator of type 2 inflammatory responses at barrier surfaces. Recent studies found dysregulation of the TSLP–TSLP receptor (TSLPR) pathway is associated with the pathogenesis of not only allergic diseases but also a wide variety of cancers including both solid tumors and hematological tumors. Thus, the blockade of TSLP represents an attractive therapeutic strategy for allergic diseases and cancer. In this study, we report the development of a novel humanized anti-TSLP monoclonal antibody (mAb) HZ-1127. Binding affinity, specificity, and ability of HZ-1127 in inhibiting TSLP were tested. HZ-1127 selectively binds to the TSLP cytokine with high affinity and specificity. Furthermore, HZ-1127 dramatically inhibits TSLP-dependent STAT5 activation and is more potent than Tezepelumab, which is an FDA-approved humanized mAb against TSLP for severe asthma treatment in inhibiting TSLP-induced CCL17 and CCL22 chemokines secretion in human peripheral blood mononuclear cells. Our pre-clinical study demonstrates that HZ-1127 may serve as a potential therapeutic agent for allergic diseases and cancer.
Description
Citation
Xiaolei Liu, Jianzhong Han, Qian Wang, Peng Wang, Li Li, Kehe Du, Fengchao Jiang, Pei Zhang, Hongjun Liu, Jian Huang, Development of a novel humanized anti-TSLP monoclonal antibody HZ-1127 with anti-allergic diseases and cancer potential, Antibody Therapeutics, Volume 7, Issue 2, April 2024, Pages 123–130, https://doi.org/10.1093/abt/tbae006
Citation to related work
Oxford University Press (OUP)
Has part
Antibody Therapeutics, Vol. 7, Iss. 2
ADA compliance
Embedded videos
License
Attribution CC BY